INEO Appoints David Wambeke to Board of Directors
Key Highlights
- ➤David Wambeke appointed to INEO’s Board of Directors
- ➤Wambeke holds approximately 19.9% of INEO’s outstanding common shares
- ➤Wambeke brings more than 20 years of capital-markets and corporate-strategy experience
- ➤Wambeke executed over $5 billion in transactions and led more than 200 equity financings
Expert Statements
Greg Watkin, Chairman and Founder of INEO
“Dave has already been a valuable resource to INEO as a significant shareholder, and we are very pleased to have him join the Board formally.”
Greg Watkin, Chairman and Founder of INEO
“He brings an unusual combination of capital markets experience, strategic thinking and hands-on public-company operating experience.”
Greg Watkin, Chairman and Founder of INEO
“As INEO continues to scale its commercial operations, expand internationally and build its recurring platform business, I believe Dave's experience will be extremely valuable to both management and the Board.”
David Wambeke, Director of INEO; Chief Business Officer of NeuroOne Medical Technologies Corporation
“After extensive due diligence on INEO's technology, I came to the conclusion that the Company has the right technology, in the right place, at the right time as retail undergoes a fundamental digital transformation.”
David Wambeke, Director of INEO; Chief Business Officer of NeuroOne Medical Technologies Corporation
“Management has executed extremely well over the past twelve months, and I'm excited to join the Board and help the Company scale and capitalize on the significant opportunity ahead.”
SURREY, BC / ACCESS Newswire / November 3, 2026 / INEO Tech Corp. (TSXV:INEO)(OTCQB:INEOF)(FSE:0OQ) (the "Company" or "INEO"), a provider of connected entrance infrastructure for modern retail, is pleased to announce the appointment of David Wambeke to the Company's Board of Directors.
Mr. Wambeke brings more than 20 years of experience across investment banking, capital markets, corporate development, investor relations and commercial strategy. He is currently Chief Business Officer of NeuroOne Medical Technologies Corporation, where he leads business development, investor relations and commercial strategy. He previously served as Chief Business Officer of DiaMedica Therapeutics Inc., where he played a central role in corporate strategy, investor relations, business development and multiple equity financings, while spearheading the Diamedica's preeclampsia initiative, which contributed to an increase of more than $200 million in shareholder value.
Get started
Create a free account to read the full story.